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Radioiodine is an effective and low-risk therapy modality in well-differentiated 
thyroid cancer patients post near-total thyroidectomy. Extra thyroidal tumors such 
as breast cancer are known to be able to uptake radioiodine. The aim of this study 
was to analyze the uptake, efflux and cytotoxicity of radioiodine for two molecular 
types of breast cancer cell lines. Two types of breast cancer cell lines were used in 
this study, MCF-7 (luminal A type) and SKBR3 (HER2 type). The HaCaT cell line 
was used as normal cells. Iodine-125 (I-125) was used to measured radioiodine 
uptake and efflux. Clonogenic assay was used to assess cytotoxicity of iodine-131 
(I-131) based on the tested cell reproductive ability. The radioiodine uptake in 
SKBR3 cells was found to be higher than that of MCF-7 and HaCaT cells at p<0.05.  
The reproductive ability of MCF-7 cells are lower than SKBR3 cells at p<0.05. 
Both breast cancer cells have less reproduction ability than HaCaT cells at p<0.05. 
Both types of breast cancer cells present the ability to uptake radioiodine and show 
a high sensitivity to radioiodine exposure. Normal cells also demonstrate an ability 
to uptake radioiodine. However, they have a better tolerance to the amount of I-131 
exposure. These findings could potentially lead to the use if I-131 for ablative 
therapy in breast cancer, similiar to its use in the treatment of thyroid cancer. 
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INTRODUCTION 
 
Breast cancer is a common malignancy 
among cancer patient women. As a systemic 
disease, it requires adjuvant therapy with hormone 
or anticancer drugs after surgery, with the aim to 
eliminate an occult micrometastatic disease and 
improving disease-free and overall survival [1]. 
However, anticancer drugs can be significantly toxic 
to normal cells. New anticancer drugs, which are 
selectively destructive to cancerous cells with 
minimum harmful effect to healthy ones, are 
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needed. Therefore, alternative therapeutic strategies 
targeting breast cancer cells selectively are the most 
promosing approach to achieve this aim. One of 
them is the radioiodine therapy. It has been used for 
well-differentiated thyroid cancer [2]. 
Radioiodine (I-131) has been used since 1946 
in integrated management of thyroid cancer for 
adjuvant therapy. This is due to its ability to 
increase the rate of patient survival compared to 
patients who do not receive I-131 [3,4]. This therapy 
is based on the uptake of radioiodine into cancer 
cells. In thyroid cancer, the uptake of I-131 is 
affected by the natrium/iodide symporter (NIS) 
expression [3,5,6]. A natrium/iodide symporter 
brings two sodium ions (Na
+
) and one iodide ion           
(I
-
) to cross the membrane against its ionic 
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concentration gradient [3,6,7]. It serves as the 
driving force for iodide uptake and is maintained by 
Na
+
/K
+
-adenosine triphosphatase (Na
+
/K
+
-ATPase). 
Natrium iodide symporter activity is necessary to 
provide iodide accumulation inside thyroid cells 
[6,7,9,14]. Beside thyroid cancer cells, NIS is also 
expressed in above 80% of invasive breast cancer 
tissue samples [8]. 
Therefore, the same approach of treatment 
could also be applied to women with breast                   
cancer because NIS is also expressed in                      
breast cancer cells. In relation to cell surface of              
NIS expression with radioiodine uptake, there                
are varieties of cell surface NIS levels of breast 
cancer cells [9]. It is crucial to define the type of 
breast cancer cells that are potential to the 
radioiodine theraphy. The luminal A is a common 
breast cancer type and it has a good prognosis.                
On the other hand, the HER2 type has a poorer 
prognosis [10,11]. The characterization of 
radioiodine uptake and cytotoxic effects to                   
cancer cells are important as a basis of the                        
use of I-131 for breast cancer treatment. The aim                
of this study is to investigate the uptake,                          
efflux, and cytotoxicity of radioiodine in the                    
MCF-7 and SKBR3 cell lines which represent                     
the luminal A and HER2 breast cancer                           
types, respectively. 
 
 
 
EXPERIMENTAL METHODS 
 
Cell culture 
 
The SKBR3, MCF-7, and HaCaT cell lines 
were used in this study. The SKBR3 cell line was 
obtained from American Type Culture Collection 
(ATCC) through National Atomic Energy Agency 
(BATAN), Puspiptek Serpong. The MCF-7 and 
HaCaT cell lines were obtained from the Faculty of 
Medicine, Padjadjaran University, Bandung, 
Indonesia. The SKBR3 cell is HER2 positive,                 
and the MCF-7 is a luminal A model [12].                           
The HaCaT line comprises normal keratin                      
cells, and in this investigation they were used                     
as a control. 
The MCF-7 and HaCaT cells were cultured       
in RPMI 1640 medium (Sigma-Aldrich)                        
while SKBR3 cells were cultured in McCoy’s 5A 
medium (Sigma-Aldrich). All cell culture                   
mediums were supplemented with 10% fetal                        
bovine serum (Sigma-Aldrich), 1% penicillin,                     
1% streptomycin, and 1% amphotericin B.                      
Cells were incubated at 37°C and supplied                        
with 5% of carbon dioxide (CO2) until                             
80% confluency. 
Radioiodine uptake 
 
Twelve-well culture plates were seeded                 
with MCF-7, SKBR3, and HaCaT cells. Assays 
were performed in triplicate. Cells were treated in 
Hanks’ balanced salt solution (HBSS) (Gibco)               
and supplemented with 7.4104 Becquerel/well                
of NaI-125 (BATAN, Indonesia), 10 mM HEPES                 
(pH 7.3) for 60 minutes at 37°C, and 5% CO2.                    
The cells were rapidly washed twice with 1 mL cold 
HBSS and incubated in 1 mL 95% ethanol at                    
room temperature for 20 minutes to release 
intracellular I-125. The supernatant was counted in a 
gamma radiation counter. The counts per minute 
were normalized to 10
6
 cell number. Untreated cells 
were used as a control. Due to its ability to emit 
low-energy gamma radiation, Iodine-125 was used 
for radioiodine uptake and efflux experiments [6]. 
This makes counting of uptake and efflux of 
radioiodine by gamma radiation counters possible.  
 
 
Radioiodine efflux 
 
Briefly, MCF-7, SKBR3, and HaCaT cells 
were incubated in HBSS and supplemented  with 
7.4104 Becquerel/well of NaI-125, 10 mM HEPES 
(pH 7.3) for 60 minutes at 37°C, and 5% CO2.                   
The medium was replaced every 15 min with fresh 
HBSS, but without I-125. The content of I-125                
in the collected supernatant was measured by 
gamma-counter. After the time end point (60 min), 
the cells were extracted with 1 mL 95% ethanol to 
count the residual radioactivity. The total uptake of 
each well was calculated as the sum of efflux 
washes and the lysate. These experiments were 
performed in triplicate. 
 
 
Clonogenic assay 
 
Briefly, MCF-7, SKBR3, and HaCaT cells 
were grown in twelve-well culture plates until 90% 
confluency. These experiments were performed in 
triplicate. The cells were then incubated for 7 h in 
5% CO2 at 37°C with HBSS containing 7.4×10
5
 
Becquerel/well NaI-131 (BATAN Indonesia), and 
10mM HEPES (pH 7.3). The reaction was 
terminated by removing the I-131 containing 
medium and the cells were washed twice with cold 
HBSS. The cells were then trypsinized, counted, and 
plated at densities of 500 and 1000 cells/well                
with growth medium in six-well culture plates.                        
The cells were then grown for 10 days, washed     
with phosphate-buffered saline (PBS), fixed with 
methanol/water (1:1), and then stained with                
crystal violet. Macroscopic colonies were counted. 
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The survival rate was calculated as the percentage of 
cell colonies in plates treated with I-131 compared 
with those treated with only HBSS. Iodine-131 was 
used for clonogenic assay. It emits beta particles 
which affect cell reproduction. 
 
 
Statistical analyses 
 
The data are expressed as mean ± standard 
deviation (SD) when distributed normally.                 
Data comparison between groups were made with 
one-way ANOVA, followed by Dunnett’s T3 test, 
with  p values < 0.05 being considered significant. 
 
 
 
RESULTS AND DISCUSSION 
 
Radioiodine uptake 
 
The radioidodine uptakes of SKBR3 and 
MCF-7 cells are compared to that of HaCaT cells. 
SKBR3 cells' uptake is found to be significantly 
higher (1765 ± 44 kcpm) when compared with both 
MCF-7 and HaCaT cells at p<0.05, as shown in  
Fig. 1. An insignificant difference was found in 
radioiodine uptake between MCF-7 and HaCaT 
cells. In our study ( the data from our another study  
and do not publish yet), MCF-7 and HaCaT cells do              
not express NIS, which is needed as iodine                     
co-transporter (unpublished data). It is assumed that 
the insignificant difference in radioidine uptake 
between MCF-7 and HaCaT cells is related to the 
absence of NIS expression in both cells. A high 
uptake of radioiodine by the cells is needed to reach 
the optimal effects of treatment. Nakamoto et al. 
197 reported, based on their in-vitro study, that there            
are two ways to increase the uptake, first by 
increasing the iodine concentration and second by                
increasing the cells numbers [1]. Another study by 
Vadysirisack  et al. also reported that radioiodine 
uptake could be elevated by increasing iodine 
concentration in the culture medium [13]. 
In our study ( the data from our another study  
and do not publish yet), NIS expression was only 
detected in SKBR3 cells (unpublished data). It was 
found that the radioiodine uptake in SKBR3 cells 
was higher than in MCF-7 cells. This might be 
attributed to NIS expression. Vadysirisack et al. 
reported that NIS level increases the radioiodine 
uptake. However, NIS cell-surface levels are                   
not associated with degrees of radioiodide                    
uptake among different cell types. It can be caused 
by cells differing in their membrane potential, 
Na
+
/K
+
 gradient, influx/efflux kinetics, iodide 
organification, and so forth [13]. 
It has also been found in this study that the 
higher radioiodine uptake of SKBR3 cells, when 
compared with MCF-7 cells, can be attributed                 
to having an association with the NIS presence                   
in SKBR3 cells. Even though NIS expression              
cannot be detected in MCF-7 cells, an uptake of 
radioiodine can be counted in these cells. 
Furthermore, Joseph et al. also reported, from               
their study, that there was an uptake of radioiodine 
by NIS negative expression of breast cancer                   
tissues [5]. It is subsequently assumed here                     
that radioiodine uptake is not only dependent                     
on NIS as co-transporter in breast cells. It is 
postulated that iodine transport in breast cells                     
can be achieved through a passive transport                             
beside of active transport with role of NIS                             
as co-transporter. Further studies are required to 
determine whether this phenomenon occurs in vivo 
which is a different microenvironment from                     
cell culture. 
 
 
 
 
Fig. 1. Radioiodine uptake in SKBR3, MCF-7, and HaCaT 
cells. 
 
Note: Each uptake was measured in kcpm/106 cells. The results 
are representative of triplicate wells. SKBR3 cells show a 
significantly higher I-125 uptake compared to MCF-7 and 
HaCaT cells. 
 
 
Radioiodine efflux 
 
Radioiodine uptake is essential for I-131 
therapy effectiveness. The retention of radioiodine 
that is effected by iodine efflux is also important 
variable. Radioiodine effluxes were determined in 
SKBR3, MCF-7, and HaCaT cells. The cells 
exhibited a slow release during the first 15 minutes. 
After 60 minutes, the residual activity of I-125 had 
decreased to 60%, 77.3%, and 83.4% in MCF-7, 
SKBR3, and HaCaT cells, respectively (see Fig. 2). 
Nakamoto et al.'s study reported that the radioiodine 
efflux of the MCF3B breast cancer cell line was 
slower than  that of FRTL5 cells, as a representative 
of thyroid cells [1].  
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Fig. 2. Iodine efflux in SKBR3, MCF-7, and HaCaT cells after 
one hour of incubation with I-125. 
 
Note: After the cells had been incubated, the buffer containing 
radioiodine was removed every 15 minutes and radioactivity 
was determined. Data are expressed as means of residual 
activity (%) of I-125 of triplicate wells. 
 
 
Clonogenic assay 
 
The cytotoxic activity of I-131 was 
investigated with clonogenic assay, based on the 
reproductive abilities of SKBR3, MCF-7, and 
HaCaT cells. This assay has been used for more 
than 50 years which enables the assessment of 
different reproductive abilities in vitro between 
treated cells with untreated ones [15]. 
Iodine-131 treatment reduced reproductive 
ability in MCF-7 and SKBR3 cells (p < 0.05) as 
shown in Fig. 3. Reproductive ability was 
determined by counting the number of colonies 
generated after ten days of radioiodine exposure. 
The colony formations of SKBR3 cells were                      
42.1% ± 3.6% and 52.6% ± 8.5% for 500 and 1000 
planted cells, respectively, while for MCF-7 cells 
they were 13.5% ± 4.2% and 22.6 % ± 4.8% for 500 
and 1000 planted cells, respectively. It was found 
that there was an insignificant difference in the 
generated number of colonies between 500 and 
1000 planted SKBR3 and MCF-7 cells. It can be 
concluded that both breast cancer cell lines respond 
to radioiodine exposure. It is assumed here that one 
of the mechanisms of iodine-131 toxicity toward 
MCF-7 cells can be through a bystander effect. 
Further investigation is needed to determine the 
correctness of this assumption. 
On the other hand, the formations of HaCaT 
cell colonies as response to I-131 were 99.6% ± 5.5 
and 98.3% ± 4.5% for 500 and 1000 planted cells, 
respectively. From this finding, it can be concluded 
that HaCaT as normal control cells do not become 
affected by radioiodine exposure. This study shows 
that the amount of uptake and efflux of radioiodine 
in HaCat cell does not relate to the cytotoxic effect.  
We need to add some explanation and make some 
changes that  relate to cells, uptake and cytotoxicity  
as below:  
Otherwise, SKBR3 showed a significantly higher 
uptake of radioiodine and reduced reproductive 
ability as shown in Fig 3. Interestingly, the               
MCF-7cell was found to be less uptake of 
radioiodine than in other cells. However, the 
radioiodine treatment showed a significantly reduce 
reproductive ability of the cell  as shown in Fig. 3.   
It can be assumed that the two types of breast  
cancer cells might have different proapoptosis genes  
expression that can influence the sensitivity toward  
radioiodine exposure. Further investigations are still 
needed to examine this finding. 
 
 
Fig. 3. Reproductive ability (%) of SKBR3, MCF-7 and HaCaT 
cells after treatment with 20µCi 7.4×105 Bq/well of I-131               
for 7 hours at 37°C. MCF-7 and SKBR3 cells have lower 
reproductive abilities than HaCaT cells at p<0.05. 
 
The radioiodine exposure to HaCaT cells, as a 
normal control, show almost no influence to the 
reproductive ability of the cells. Extra-thyroid cells 
are reported also to be able to take up iodine-131, 
including salivary glands, stomach and lacrimal 
glands. However, radioiodine uptake in those cells 
can be tolerated well [5,6]. 
Several factors influence the toxic effects in 
cells during radioiodine exposure, including the 
amount of uptake, retention time, and biological half 
life. Additionally, cell sensitivity toward radiation, 
which is influenced by microenvironment and  
proapoptosis genes expression, also plays an 
important role. These factors can influence the cells' 
response toward radioiodine exposure [16].  
In this study, normal cells, which receive 
certain amount of radioiodine, did not show any 
toxic effect. Instead, it reduced the reproductive 
ability of MCF-7 and SKBR3 cells significantly. 
These results could indicate advantages for 
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radioiodine as a therapy agent for breast cancer. 
Further studies are still needed in order to determine 
the role of radioiodine in reducing the reproductive 
ability of breast cancer cells. 
 
 
 
CONCLUSION 
 
The ability of the breast cancer cells in taking 
up radioiodine and suppressing cells reproductivity 
has led to a potential of I-131 to be used for ablative 
therapy in breast cancer which is analogous to its 
employment in the treatment of thyroid cancer. 
Further studies are required regarding the iodide 
transport in breast cells that is expected to be able to 
provide a new therapeutic pathway. 
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